HLS Therapeutics Inc. (HLS.TO)
CAD 4.4
(0.92%)
CAD 4.4
(0.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 111.36 Million USD | -4.27% |
| 2022 | 116.33 Million USD | 1.01% |
| 2021 | 115.16 Million USD | -14.47% |
| 2020 | 134.65 Million USD | -4.82% |
| 2019 | 141.47 Million USD | -4.37% |
| 2018 | 147.93 Million USD | -27.58% |
| 2017 | 204.26 Million USD | 36901.53% |
| 2016 | 552.04 Thousand USD | -3.52% |
| 2015 | 572.17 Thousand USD | -95.74% |
| 2014 | 13.41 Million USD | -6.1% |
| 2013 | 14.28 Million USD | 64.46% |
| 2012 | 8.68 Million USD | -35.4% |
| 2011 | 13.44 Million USD | 10.51% |
| 2010 | 12.16 Million USD | -30.62% |
| 2009 | 17.53 Million USD | 0.07% |
| 2008 | 17.52 Million USD | -37.18% |
| 2007 | 27.89 Million USD | 50.64% |
| 2006 | 18.52 Million USD | 30.65% |
| 2005 | 14.17 Million USD | 22.65% |
| 2004 | 11.55 Million USD | -22.0% |
| 2003 | 14.81 Million USD | 255.47% |
| 2002 | 4.16 Million USD | -29.57% |
| 2001 | 5.91 Million USD | -54.82% |
| 2000 | 13.09 Million USD | -43.87% |
| 1999 | 23.33 Million USD | 31.05% |
| 1998 | 17.8 Million USD | -25.92% |
| 1997 | 24.03 Million USD | 138.23% |
| 1996 | 10.09 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 108.61 Million USD | -0.06% |
| 2024 Q1 | 108.68 Million USD | -2.4% |
| 2023 FY | 111.36 Million USD | -4.27% |
| 2023 Q1 | 115.26 Million USD | -0.92% |
| 2023 Q2 | 115.38 Million USD | 0.1% |
| 2023 Q3 | 113.42 Million USD | -1.7% |
| 2023 Q4 | 111.36 Million USD | -1.82% |
| 2022 FY | 116.33 Million USD | 1.01% |
| 2022 Q2 | 122.22 Million USD | 9.63% |
| 2022 Q1 | 111.49 Million USD | -3.19% |
| 2022 Q3 | 118.88 Million USD | -2.73% |
| 2022 Q4 | 116.33 Million USD | -2.15% |
| 2021 Q1 | 129.27 Million USD | -4.0% |
| 2021 FY | 115.16 Million USD | -14.47% |
| 2021 Q3 | 119.21 Million USD | -5.59% |
| 2021 Q4 | 115.16 Million USD | -3.39% |
| 2021 Q2 | 126.27 Million USD | -2.32% |
| 2020 Q1 | 136.91 Million USD | -3.22% |
| 2020 Q4 | 134.65 Million USD | -1.82% |
| 2020 FY | 134.65 Million USD | -4.82% |
| 2020 Q3 | 137.14 Million USD | 11.27% |
| 2020 Q2 | 123.25 Million USD | -9.98% |
| 2019 Q1 | 142.86 Million USD | -3.43% |
| 2019 Q4 | 141.47 Million USD | 4.94% |
| 2019 FY | 141.47 Million USD | -4.37% |
| 2019 Q2 | 141.64 Million USD | -0.85% |
| 2019 Q3 | 134.81 Million USD | -4.82% |
| 2018 FY | 147.93 Million USD | -27.58% |
| 2018 Q1 | 196.12 Million USD | -3.98% |
| 2018 Q2 | 183.52 Million USD | -6.42% |
| 2018 Q3 | 155.93 Million USD | -15.04% |
| 2018 Q4 | 147.93 Million USD | -5.13% |
| 2017 FY | 204.26 Million USD | 36901.53% |
| 2017 Q4 | 204.26 Million USD | 26742.76% |
| 2017 Q3 | 760.96 Thousand USD | 36.89% |
| 2017 Q2 | 555.91 Thousand USD | 11.48% |
| 2017 Q1 | 498.65 Thousand USD | -9.67% |
| 2016 Q2 | 469.16 Thousand USD | 15.56% |
| 2016 Q3 | 532.42 Thousand USD | 13.48% |
| 2016 Q4 | 552.04 Thousand USD | 3.69% |
| 2016 FY | 552.04 Thousand USD | -3.52% |
| 2016 Q1 | 405.99 Thousand USD | -29.04% |
| 2015 Q4 | 572.17 Thousand USD | -9.42% |
| 2015 Q2 | 919.99 Thousand USD | -75.53% |
| 2015 FY | 572.17 Thousand USD | -95.74% |
| 2015 Q3 | 631.65 Thousand USD | -31.34% |
| 2015 Q1 | 3.76 Million USD | -71.98% |
| 2014 FY | 13.41 Million USD | -6.1% |
| 2014 Q1 | 13.32 Million USD | -6.75% |
| 2014 Q3 | 18.99 Million USD | 6.68% |
| 2014 Q4 | 13.41 Million USD | -29.37% |
| 2014 Q2 | 17.8 Million USD | 33.65% |
| 2013 Q3 | 11.02 Million USD | 7.91% |
| 2013 FY | 14.28 Million USD | 64.46% |
| 2013 Q4 | 14.28 Million USD | 29.63% |
| 2013 Q2 | 10.21 Million USD | 48.67% |
| 2013 Q1 | 6.87 Million USD | -20.91% |
| 2012 Q4 | 8.68 Million USD | -54.48% |
| 2012 Q3 | 19.08 Million USD | 31.69% |
| 2012 FY | 8.68 Million USD | -35.4% |
| 2012 Q2 | 14.49 Million USD | 33.25% |
| 2012 Q1 | 10.87 Million USD | -19.12% |
| 2011 Q3 | 11.29 Million USD | -1.97% |
| 2011 Q2 | 11.52 Million USD | 9.02% |
| 2011 Q1 | 10.57 Million USD | -13.12% |
| 2011 FY | 13.44 Million USD | 10.51% |
| 2011 Q4 | 13.44 Million USD | 19.02% |
| 2010 Q2 | 14.39 Million USD | 25.34% |
| 2010 Q3 | 13.73 Million USD | -4.62% |
| 2010 Q4 | 12.16 Million USD | -11.38% |
| 2010 Q1 | 11.48 Million USD | -34.51% |
| 2010 FY | 12.16 Million USD | -30.62% |
| 2009 Q4 | 17.53 Million USD | -3.19% |
| 2009 FY | 17.53 Million USD | 0.07% |
| 2009 Q1 | 15.85 Million USD | -9.55% |
| 2009 Q2 | 17.87 Million USD | 12.75% |
| 2009 Q3 | 18.11 Million USD | 1.36% |
| 2008 FY | 17.52 Million USD | -37.18% |
| 2008 Q4 | 17.52 Million USD | -16.15% |
| 2008 Q1 | 24.14 Million USD | -13.47% |
| 2008 Q2 | 26.91 Million USD | 11.5% |
| 2008 Q3 | 20.9 Million USD | -22.35% |
| 2007 Q4 | 27.89 Million USD | 32.13% |
| 2007 Q2 | 18.66 Million USD | -8.86% |
| 2007 Q1 | 20.47 Million USD | 10.56% |
| 2007 FY | 27.89 Million USD | 50.64% |
| 2007 Q3 | 21.11 Million USD | 13.14% |
| 2006 FY | 18.52 Million USD | 30.65% |
| 2006 Q4 | 18.52 Million USD | 25.81% |
| 2006 Q3 | 14.72 Million USD | -9.08% |
| 2006 Q2 | 16.19 Million USD | 6.86% |
| 2006 Q1 | 15.15 Million USD | 6.88% |
| 2005 Q4 | 14.17 Million USD | 16.74% |
| 2005 Q3 | 12.14 Million USD | 27.22% |
| 2005 Q2 | 9.54 Million USD | -6.91% |
| 2005 Q1 | 10.25 Million USD | -11.28% |
| 2005 FY | 14.17 Million USD | 22.65% |
| 2004 Q1 | 15.32 Million USD | 3.43% |
| 2004 FY | 11.55 Million USD | -22.0% |
| 2004 Q3 | 12.06 Million USD | -9.87% |
| 2004 Q2 | 13.38 Million USD | -12.63% |
| 2004 Q4 | 11.55 Million USD | -4.22% |
| 2003 Q4 | 14.81 Million USD | -6.92% |
| 2003 FY | 14.81 Million USD | 255.47% |
| 2003 Q1 | 16.56 Million USD | 297.5% |
| 2003 Q2 | 16.49 Million USD | -0.47% |
| 2003 Q3 | 15.91 Million USD | -3.47% |
| 2002 Q4 | 4.16 Million USD | 7.45% |
| 2002 Q1 | 2.78 Million USD | -52.98% |
| 2002 Q2 | 3.2 Million USD | 15.23% |
| 2002 Q3 | 3.87 Million USD | 20.99% |
| 2002 FY | 4.16 Million USD | -29.57% |
| 2001 FY | 5.91 Million USD | -54.82% |
| 2001 Q1 | 10.86 Million USD | -17.02% |
| 2001 Q2 | 7.45 Million USD | -31.45% |
| 2001 Q3 | 7.28 Million USD | -2.23% |
| 2001 Q4 | 5.91 Million USD | -18.75% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | 13.09 Million USD | -43.87% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q4 | 13.09 Million USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | 23.33 Million USD | 31.05% |
| 1999 Q1 | - USD | -100.0% |
| 1999 Q4 | 23.33 Million USD | 0.0% |
| 1998 FY | 17.8 Million USD | -25.92% |
| 1998 Q4 | 17.8 Million USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 FY | 24.03 Million USD | 138.23% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | 10.09 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aurora Cannabis Inc. | 236.8 Million CAD | 52.972% |
| Avicanna Inc. | 13.99 Million CAD | -695.507% |
| Avant Brands Inc. | 33.22 Million CAD | -235.188% |
| Cardiol Therapeutics Inc. | 8.45 Million CAD | -1217.282% |
| Crescita Therapeutics Inc. | 5.77 Million CAD | -1828.03% |
| Knight Therapeutics Inc. | 198.62 Million CAD | 43.932% |
| MediPharm Labs Corp. | 10.93 Million CAD | -918.688% |
| OrganiGram Holdings Inc. | 26.83 Million CAD | -315.038% |
| Canopy Growth Corporation | 799.82 Million CAD | 86.077% |
| Willow Biosciences Inc. | 3.23 Million CAD | -3340.315% |
| Auxly Cannabis Group Inc. | 210.85 Million CAD | 47.186% |